Related Experiment Video
Updated: Jul 26, 2025
DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
Published on: February 27, 2014
Lipids, lipid-lowering agents, and inflammatory bowel disease: a Mendelian randomization study
Heqing Tao1, Zhou Yu2, Yongqiang Dong3
1Department of Gastroenterology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
High-density lipoprotein cholesterol (HDL-C) is causally linked to inflammatory bowel disease (IBD). Genetic inhibition of PCSK9 increases IBD risk, while CETP inhibition decreases Crohn's disease risk.
Area of Science:
- Genetics
- Gastroenterology
- Pharmacology
Background:
- Lipid traits are implicated in inflammatory bowel disease (IBD) pathogenesis.
- Understanding the causal role of lipids and lipid-lowering agents in IBD is crucial for therapeutic development.
Purpose of the Study:
- To investigate the causal relationships between key lipid traits (LDL-C, TG, HDL-C) and IBD.
- To assess the impact of lipid-lowering agents on IBD risk using genetic approaches.
Main Methods:
- Univariable and multivariable Mendelian randomization (MR) analyses were performed.
- Drug-targeted MR and network MR were employed to examine drug effects and mediation pathways.
Main Results:
- High-density lipoprotein cholesterol (HDL-C) showed an inverse association with Crohn's disease (CD) risk.
- Genetic inhibition of PCSK9 was associated with increased risk for IBD, ulcerative colitis (UC), and CD.
- Genetic inhibition of CETP was associated with decreased risk for CD, with HDL-C mediating this pathway.
Conclusions:
- A causal link exists between HDL-C levels and IBD, UC, and CD.
- Targeting PCSK9 may increase IBD risk, whereas CETP inhibition might reduce CD risk.
- Further research is warranted to elucidate the long-term effects of lipid-lowering drugs on gastrointestinal conditions.
More Related Videos
09:15Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
Related Concept Videos
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...